Stay updated on Pembrolizumab in Nasopharyngeal Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Nasopharyngeal Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab in Nasopharyngeal Carcinoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded site revision indicator 'Revision: v3.4.2' and removed the prior 'lapse in government funding' notice and the 'Revision: v3.4.1' notice. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a site-wide notice about government funding and NIH Clinical Center operations, and updated the page revision to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedThe page received minor UI/label updates: a 'Show glossary' option was added, the update-history line now reads 'Last Update Submitted that Met QC Criteria' with capitalization tweaks, 'No FEAR Act Data' was standardized to 'No FEAR Act data', and the revision tag was changed to 'Revision: v3.4.0'.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page now displays Revision: v3.3.4, replacing the previous Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedThe page footer removes the HHS Vulnerability Disclosure link and adds a new revision note, Revision: v3.3.3 (replacing the previous v3.3.2).SummaryDifference0.1%

- Check92 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Nasopharyngeal Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Nasopharyngeal Carcinoma Clinical Trial page.